103 related articles for article (PubMed ID: 32572907)
1. LncRNA CDKN2BAS aggravates the progression of ovarian cancer by positively interacting with GAS6.
Wang HM; Shen SL; Li NM; Su HF; Li WY
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):5946-5952. PubMed ID: 32572907
[TBL] [Abstract][Full Text] [Related]
2. LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1.
Pei CL; Fei KL; Yuan XY; Gong XJ
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10657-10663. PubMed ID: 31858532
[TBL] [Abstract][Full Text] [Related]
3. LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis.
Rui X; Wang L; Pan H; Gu T; Shao S; Leng J
J Cell Mol Med; 2019 Feb; 23(2):865-876. PubMed ID: 30394665
[TBL] [Abstract][Full Text] [Related]
4. LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.
Sun D; Fan XH
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2345-2352. PubMed ID: 30964158
[TBL] [Abstract][Full Text] [Related]
5. PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.
Liu XL; Liu HM; Han N; Li FH; Sun F; Fan DM; Xu Q
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8239-8248. PubMed ID: 31646554
[TBL] [Abstract][Full Text] [Related]
6. RBBP6 aggravates the progression of ovarian cancer by targeting PIK3R6.
Liu YJ; Cui LL; Liu ZS; Jia RY; Ding YX; Xu LZ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10366-10374. PubMed ID: 33155192
[TBL] [Abstract][Full Text] [Related]
7. LncRNA GIHCG promotes development of ovarian cancer by regulating microRNA-429.
Yao N; Yu L; Zhu B; Gan HY; Guo BQ
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8127-8134. PubMed ID: 30556850
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA LINC00152 is up-regulated in ovarian cancer tissues and regulates proliferation and cell cycle of SKOV3 cells.
Ni H; Niu LL; Tian SC; Jing LK; Zhang LT; Lin QQ; Cai YH; Liang HM; Du Q; Li H
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9803-9813. PubMed ID: 31799647
[TBL] [Abstract][Full Text] [Related]
9. LncRNA AWPPH accelerates the progression of non-small cell lung cancer by sponging miRNA-204 to upregulate CDK6.
Wu D; Qin BY; Qi XG; Hong LL; Zhong HB; Huang JY
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4281-4287. PubMed ID: 32373964
[TBL] [Abstract][Full Text] [Related]
10. LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis.
Chen J; Huang X; Wang W; Xie H; Li J; Hu Z; Zheng Z; Li H; Teng L
Aging (Albany NY); 2018 Nov; 10(11):3371-3381. PubMed ID: 30510148
[TBL] [Abstract][Full Text] [Related]
11. USF1-mediated upregulation of lncRNA GAS6-AS2 facilitates osteosarcoma progression through miR-934/BCAT1 axis.
Wei G; Zhang T; Li Z; Yu N; Xue X; Zhou D; Chen Y; Zhang L; Yao X; Ji G
Aging (Albany NY); 2020 Apr; 12(7):6172-6190. PubMed ID: 32269179
[TBL] [Abstract][Full Text] [Related]
12. The carcinogenic complex lncRNA DUXAP8/EZH2/LSD1 accelerates the proliferation, migration and invasion of colorectal cancer.
Gong A; Huang Z; Ge H; Cai Y; Yang C
J BUON; 2019; 24(5):1830-1836. PubMed ID: 31786844
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of long non-coding RNA GAS5 promotes cell proliferation, migration and invasion, and indicates a poor prognosis in ovarian cancer.
Li J; Huang H; Li Y; Li L; Hou W; You Z
Oncol Rep; 2016 Dec; 36(6):3241-3250. PubMed ID: 27779700
[TBL] [Abstract][Full Text] [Related]
14. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
Yao N; Sun JQ; Yu L; Ma L; Guo BQ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
[TBL] [Abstract][Full Text] [Related]
15. Effects of LncRNA KCNQ1OT1 on proliferation and migration of ovarian cancer cells by Wnt/β-catenin.
Luo ZP; Jin H
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8788-8794. PubMed ID: 31696465
[TBL] [Abstract][Full Text] [Related]
16. Lnc00908 promotes the development of ovarian cancer by regulating microRNA-495-5p.
Jiang JN; Hong QY; Gao HJ; Lai BL; Lan JF; Yang Q
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1388-1396. PubMed ID: 30840259
[TBL] [Abstract][Full Text] [Related]
17. Linc-UBC1 stimulates the metastasis and progression of ovarian cancer via downregulating p53 level.
Liu H; Zeng SY; Xie Y; Fei CQ; Sun L
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1054-1061. PubMed ID: 32096175
[TBL] [Abstract][Full Text] [Related]
18. LncRNA PCAT6 promotes occurrence and development of ovarian cancer by inhibiting PTEN.
Kong FR; Lv YH; Yao HM; Zhang HY; Zhou Y; Liu SE
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8230-8238. PubMed ID: 31646553
[TBL] [Abstract][Full Text] [Related]
19. LncRNA snaR upregulates GRB2-associated binding protein 2 and promotes proliferation of ovarian carcinoma cells.
Huang Y; Hu Y; Jin Z; Shen Z
Biochem Biophys Res Commun; 2018 Sep; 503(3):2028-2032. PubMed ID: 30093110
[TBL] [Abstract][Full Text] [Related]
20. LncRNA MIF-AS1 aggravates the progression of ovarian cancer by sponging miRNA-31-5p.
Fan Y; Wang L; Han XC; Ma HY; Zhang N; Zhe L
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2248-2255. PubMed ID: 32196575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]